梅特福林的使用与青少年和年轻成年人的喘恶化减少有关
Erhan Ararat1, Reid D Landes2, Erick Forno3
1Department of Pediatrics, Division of Pulmonology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Pediatric pulmonology
|September 29, 2023
概括
在患有喘的青少年和年轻成年人中使用甲胺与喘恶化率的降低有关. 对甲胺处方的更高遵守与恶化的更大减少相关,这表明对喘管理的潜在益处.
科学领域:
- 儿科肺病学 儿科肺病学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 甲福明是一种抗糖尿病药物,表现出抗炎和抗氧化特性.
- 之前的研究表明,甲福明的使用与成人喘恶化减少有关.
- 甲胺对青少年和年轻人的喘恶化的影响仍在调查中.
研究的目的:
- 评估青少年和年轻人的喘恶化率在开始服用甲福林后发生的变化.
- 为了确定甲福明的处方遵守是否会影响恶化率的这些变化.
主要方法:
- 对12至20岁的喘患者和甲胺处方的电子健康记录的回顾性分析.
- 估计每年喘恶化率在开始服用甲福尔之前和之后.
- 用于评估处方坚持和恶化率变化之间的关联的回归模型,以混因素进行调整.
主要成果:
- 在门诊喘恶化率的统计学上显著下降被观察到后metformin处方 (13.4%至7.8%,p=0.009).
- 增加对甲胺处方的坚持显示出与年度喘恶化率的较大降低有显著的相关性 (排名r=-0.165,p<0.001).
- 在调整了年龄,性别,BMI和吸入性皮质类固醇使用后,甲福林与减少恶化之间的关联减弱了.
结论:
- 甲胺处方与青少年和年轻成年人喘恶化率的降低有关.
- 需要对更大的样本大小和对照组进行进一步的研究,以确认甲胺是否直接驱动这些恶化的减少.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Antiasthma Drugs: Methylxanthines
261
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
261
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338
Antiasthma Drugs: β2-Adrenoceptor Agonists
290
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
290
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K


